A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity
about
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorRegulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interactionRegulation of immune cell function and differentiation by the NKG2D receptorCommentary on CAM and NK Cells by Kazuyoshi Takeda and Ko OkumuraScreening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytesF4/80+ Host Macrophages Are a Barrier to Murine Embryonic Stem Cell-Derived Hematopoietic Progenitor Engraftment In Vivo.NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes.Immunology of naturally transmissible tumours.Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cellsTranscription analysis on response of porcine alveolar macrophages to Haemophilus parasuis.Regulation of ligands for the NKG2D activating receptor.Costimulation of dendritic epidermal gammadelta T cells by a new NKG2D ligand expressed specifically in the skinRAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphomaOncogenic stress sensed by the immune system: role of natural killer cell receptorsGenetics, genomics, and evolutionary biology of NKG2D ligands.NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity.Cancer immunotherapy and heat-shock proteins: promises and challenges.Activation of natural killer cells: underlying molecular mechanisms revealed.Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.Interplay of natural killer cells and their receptors with the adaptive immune response.Viral modulation of NK cell immunity.NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responsesReprogramming of CTLs into natural killer-like cells in celiac diseaseThe role of NKG2D signaling in inhibition of cytotoxic T-lymphocyte lysis by the Murine cytomegalovirus immunoevasin m152/gp40NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145.Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn.Immunosurveillance and immunotherapy of tumors by innate immune cells.The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions.JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicityPhysiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity.Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.Regulation of ligands for the activating receptor NKG2D.Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress.p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cellsNK cells and cancer immunosurveillance.NKG2D ligands in tumor immunity.
P2860
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
P248
Q24306696-E27367C3-BA79-414E-AC63-CD26FDC5CF78Q24309134-7AAD19B1-6977-4A51-9B48-F0CF1E868A40Q24635093-D0B28F94-BDCE-4331-BBFB-12309BE35A75Q24799003-2B59745E-1AFA-47EE-B3B7-AA54C1840B91Q24811648-66729E00-4613-454F-AFB6-27CA7C3DF748Q28592638-51FB01AE-ED67-44D8-B160-0255894E1CBAQ30828462-CE9AB135-922D-4526-BEAB-CC95C38EAEE2Q33887452-19D70E59-8883-4B70-89C7-E483C6A370E0Q33987473-746F3518-938C-46F8-9574-06C6F01047E3Q34041901-0C85D34B-D317-46C3-8659-4BDF561C3AEAQ34055580-68B95B8C-CEAB-42D5-9A53-547857705225Q34157917-216EF7D9-602D-4510-9F9C-FC22B3CC4E64Q34321457-9423854F-21F8-4F22-8718-13669825FFBEQ34402566-E05B50A7-C797-4E55-85E5-329D46EFB7F5Q34407976-15CA77B8-83D2-4864-8B7D-61CC2B09179DQ34473267-7A6462E2-65BD-4EA8-94B9-D523F0190D50Q34489980-5861AA9B-3BA3-4084-9182-9EB5569FB74FQ35470503-0577CA95-1898-4D33-AD19-E0068A7C24C7Q35684868-A941670C-C648-400D-A8AE-6587C0A02A6CQ35828150-ACC42148-D6A9-44B3-B409-0BDD9BEBF744Q35876982-465D5DBB-616A-494D-99ED-689912646DC5Q35902972-ECAB19CF-40CF-4453-A292-5E62DB787EADQ35904393-26F4055E-C353-4377-ACBC-574C91D4E9CDQ35988761-F2F89EE1-095B-4854-BDF5-F3F996ED13C8Q36215821-D3401ABF-FFB0-4369-8FC0-D50A04BF2A59Q36238119-FE632B79-9664-4DDA-9BA2-F5A45D2827D0Q36315486-082CB3DE-5CFF-4AF5-B4BA-DFF4A05C9181Q36399548-CD6FA3AB-F033-4AA6-B50D-B5EB603DC49BQ36402602-B42B2020-561D-4A11-AB4C-A860E77A97EFQ36402936-508906E6-5F0F-4DBA-9185-C9CEA2993CC0Q36471212-9CAA93AD-85BC-42DC-A3F4-C0D82558D3CAQ36493807-F7F5BA36-5CEA-454D-A933-C7426280EC65Q36498465-70C82ADF-29EF-4EDE-81BF-4BE8B06AAC6DQ36652177-99A0A691-1AA8-4ACD-9D2D-287B23820166Q36810264-21EC6E89-27CE-4C5E-93DC-77C33B1625BBQ36872056-B91472FD-246C-4849-AFC6-74B60B2954FEQ37106794-2BAC1B64-80D4-4147-9A74-0FD56B8845E8Q37194949-E1430E7D-E485-4C46-A6EB-E4BFE0987B1FQ37287176-340175EB-00E2-4671-A1FF-EB4D31148B25Q37287179-47E8E62E-775A-4C28-85CC-F636D9FD84E6
P2860
A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity
description
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im Februar 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/02/01)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/02/01)
@nl
наукова стаття, опублікована в лютому 2003
@uk
مقالة علمية (نشرت في فبراير 2003)
@ar
name
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@ast
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@en
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@nl
type
label
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@ast
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@en
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@nl
prefLabel
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@ast
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@en
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@nl
P2093
P921
P3181
P356
P1476
A novel ligand for the NKG2D r ...... ges and induces tumor immunity
@en
P2093
Andreas Diefenbach
Jennifer K Hsia
Ming-Yu B Hsiung
P304
P3181
P356
10.1002/IMMU.200310012
P407
P577
2003-02-01T00:00:00Z